Catherine Acquadro, Global Lead Scientific Presentation and Publications, MAPI Group

Einar Andreassen, Senior Adviser, Norwegian Medicines Agency

Diego Ardigo, Project Lead, CHIESI Farmaceutici Spa

Segolene Ayme, Founder of Orphanet & Rare Disease Expert in Residence, Inserm

Michelle Berg, Vice President, Patient Advocacy, Abeona Therapeutics Inc.

Robert Bezar, EU+ Head of Medical Affairs, SMA, Biogen International GmbH

Robert Bezar at World Orphan Drug Congress

Stella Blackburn, Vice President, Global Head of Risk Management, Real-World & Late Phase Research, Quintiles

Dr Jane Blyth, Scientific Director, Complete HealthVizion

Nadia Bodkin, Founder, EDSers United & Community Engagement Team Leader, rareLife solutions

Nicole Boice, President and Founder, Global Genes Project

Vanessa Boulanger, Director of Research Programs, NORD

Dr Woody Bryan, Senior Vice President, Business Development and Licensing, Sucampo Pharmaceuticals Inc

Ivana Cattaneo, Director, Market Access and External Affairs, Novartis

Ivana Cattaneo at World Orphan Drug Congress

Fleur Chandler, Therapy Area Head of Respiratory Value Evidence and Outcomes, GlaxoSmithKline Biologicals

Fleur Chandler at World Orphan Drug Congress

Emily Crossley, Co-founder, Duchenne U.K.

Emily Crossley at World Orphan Drug Congress

Emily Culme-Seymour, External Strategy Manager, Gene Therapy, GSK

David Dasberg, Managing Director, Facio Therapies BV

Dr Francesco De Rubertis, Partner, Medicxi Ventures

Dr Renato Dellamano, President, Medical Marketing Economics

Debbie Drell, Director of Membership, National Organization for Rare Disorders

David Elvira Martinez, Director, CatSalut, Catalunya Health Service

Begonya Nafria Escalera, Patient Advocacy Manager, Sant Joan de Déu Children's Hospital

Lucia Faccio, Head of Research Development Office, Fondazione Telethon

Lucia Faccio at World Orphan Drug Congress

Davide Finocchiaro, Global Pricing & Market Access Specialist, Chiesi

Rob Fox, Head of EU Business Development, Idis Managed Access

Kelly Franchetti, Vice President, Global Patients Insights and Engagement, Mapi Group

Pedro Franco, Director for Europe for Global Regulatory and Scientific Policy, Merck Serono

Pedro Franco at World Orphan Drug Congress

Prof. Bobby Gaspar, Professor of Paediatrics & Immunology, UCL Great Ormond Street Institute of Child Health

Josie Godfrey, Director at JG Zebra Consulting, Former Associate Director of HST, National Institute for Health and Care Excellence

Josie Godfrey at World Orphan Drug Congress

Rory Graham, Senior Director of Regulatory Affairs, Mapi Group

Jim Green, President, International Niemann-Pick Disease Aliance

Jim Green at World Orphan Drug Congress

Rachel Haurwitz, President and Chief Executive Officer, Caribou Biosciences

Patrick Hopkinson, Executive Director, WWHEOR Markets, Bristol Myers Squibb

Lynne Hughes, Vice President & Head, Centre of Excellence, Neurology, Therapeutic & Speciality Business Development, Quintiles Inc

Lynne Hughes at World Orphan Drug Congress

Wills Hughes-Wilson, Senior Vice President, Chief Patient Access Officer, Sobi

Adam Hutchings, Managing Director, Dolon

Williams Hywel, Senior Research Associate, UCL

Williams Hywel at World Orphan Drug Congress

Raul Insa, Founder and Chief Executive Officer, SOM Biotech SL

Raul Insa at World Orphan Drug Congress

Edmund Jessop, Medical Adviser, National Health Service

Edmund Jessop, Medical Adviser, National Health Service

M Ken Kengatharan, Managing Director, Atheneos Capital and Chairman, Armetheon Inc

Alastair Kent OBE, Ambassador, Genetic Alliance U.K.

Dr Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

Takashi Kei Kishimoto, Chief Science Officer, Selecta Biosciences Inc

Anja Kladar, Project Manager, Croatian Alliance for Rare Diseases

Maryna Kolochavina, Project Director, RWLP Operations, Europe and Asia Pacific, INC Research/inVentiv Health

Pierre Laurin, Chief Executive Officer, ProMetic Life Sciences Inc.

Pierre Laurin at World Orphan Drug Congress

Yann Le Cam, Chief Executive Officer, EURORDIS

Prof Michael Linden, VP Gene Therapy & Head, GMI, Pfizer

Douglas Lundin, Chief Economist, The Dental and Pharmaceutical Benefits Agency T.L.V.

Tiziana Magni, Global Pricing & Market Access Specialist, CHIESI FARMACEUTICI SPA

Dr Will Maier, Chief Scientific Officer, Mapi Group

Dr Timothy J. Miller, President and CEO, Abeona Therapeutics

Ana Mingorance, Principal, Dracaena Consulting

Juliet Moritz, Executive Director, Patient Engagement & Strategic Development, Premier Research

Arnold Munnich, co-founder, Imagine Institute

Dr Michael Murphy, Chief Medical Officer, Worldwide Clinical Trials

Dr Alexander Natz, Secretary General, EUCOPE

Sandra Nestler-Parr., Director of Rare Access and Trustee, Alpha 1 UK

Judith Ng-Cashin, Chief Scientific Officer, INC Research

Dr Jane Nunn, Head of Operations, Complete HealthVizion

Tara Omeara, Vice President of Clinical Development Operations, bluebird bio

Mareike Ostertag, Director Regulatory and Science Policy, Novartis Pharma AG

Francis Pang, VP of Global Market Access, Amicus Therapeutics Inc

Francis Pang at World Orphan Drug Congress

Samantha Parker, SVP patient access, Lysogene

Kay Parkinson, CEO & Founder, Alström Syndrome UK and Chief Executive Officer, Cambridge Rare Disease Network

David Pearce, Executive Vice President of Innovation and Research, Sanford Research

Scott L Pescatore, Oncology General Manager. Rare Diseases, Novartis

Scott L Pescatore at World Orphan Drug Congress

Marco Petschulies, Scientific Advisor, G-BA

Marco Petschulies at World Orphan Drug Congress

Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche

Krzysztof Potempa, CEO, Braincures

Emiliangelo Ratti, Senior Vice President and Head of C.N.S. Therapeutic Area Unit, Takeda Pharmaceuticals International Ltd

Emiliangelo Ratti at World Orphan Drug Congress

Frederic Revah, Chief Executive Officer, Genethon

George Reynolds, CCO, Vitro Software

Diana Ribeiro, Director of Research, Action Duchenne

Marc Riviere, General Partner, T.V.M. Life Science Management Gmbh

Dr Paul Robinson, Executive Director, Patient Perspective, Merck Sharp and Dohme

Subhasis Roy, Managing Partner, Sirius Healthcare Partners Gmbh

Dr Carina Schey, PhD Researcher, University of Groningen

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA Health Sciences

Sophie Schmitz, Partner, Partners4Access

Matthias P. Schönermark, M.D., Ph.D., Managing Director, SKC Beratungsgesellschaft

Raghuram Selvaraju, M.B.A., Managing Director, Senior Analyst, Healthcare, Rodman & Renshaw

Dr Bruno Sepodes, Chair, Committee for Orphan Medicinal Products (COMP), European Medicines Agency

Mathieu Simon, Executive Vice President and Chief Operating Officer, Cellectis Therapeutics

Jan Span, Member of the Cross-Committee Task Force on Registries and Senior Clinical Assessor, Medicines Evaluation Board The Netherlands

Jan Span at World Orphan Drug Congress

Dr Andrea Spezzi, Chief Medical Officer and R&D Head, Orchard Therapeutics

Heide Stirnadel-Farrant, Director Epidemiology, GSK Fellow, Real World Evidence and Epidemiology, GSK

Andrew Storey, Vice President of Global Regulatory Strategy, AbbVie

Rick Thompson, Scientific Officer, Findacure

Marie Trad, Executive Medical Director, Quintiles Inc

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Birgitte Volck, Senior Vice President, Head of R&D Rare Diseases, GlaxoSmithKline

Julie Walters, Founder, Raremark

Rob Walton, Managing Partner, Cello Health Public Affairs

Christina Waters, CEO and Founder, RARE Science

Diane White, Assoc. Dir Development Sciences, Biomarin

Pawel Wozniak, Managing Director, Komtur Polska

Pawel Wozniak at World Orphan Drug Congress

Dr Stephen Wright, Chief Medical Officer, GW Pharmaceuticals

Stephen Yoo, Chief Medical Officer, ReGenXBio

Martine Zimmermann, Senior Vice President, Head of Global Regulatory Affairs, Alexion Pharmaceuticals